Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Datasets
Search by expertise, name or affiliation
Ozanimod induction and maintenance treatment for ulcerative colitis
TOUCHSTONE Study Group
Medicine, Gastroenterology Division
Research output
:
Contribution to journal
›
Article
›
peer-review
312
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ozanimod induction and maintenance treatment for ulcerative colitis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Ozanimod
100%
Placebo
57%
Remission
21%
Ulcerative Colitis
21%
Diseases
14%
Adverse Event
7%
Disease Activity
7%
Rectum Hemorrhage
7%
Anemia
7%
Headache
7%
Receptor Subtype
7%
Agonist
7%
Sphingosine 1 Phosphate Receptor
7%
Blindness
7%
Immunology and Microbiology
Ozanimod
100%
Ulcerative Colitis
21%
Dose
21%
Lymphocyte
14%
Agonist
7%
Peripheral Blood Lymphocyte
7%
Lymphocyte Count
7%
Gastrointestinal Tract
7%
INIS
diseases
21%
comparative evaluations
21%
lymphocytes
21%
doses
21%
patients
14%
testing
7%
range
7%
adults
7%
maintenance
7%
safety
7%
receptors
7%
phosphates
7%
induction
7%
anemias
7%
rectum
7%
gastrointestinal tract
7%
Neuroscience
Placebo
57%
Agonist
7%
Receptor Subtype
7%
Sphingosine-1-Phosphate Receptor
7%